A normative study of the components of niprisan-An herbal medicine for sickle cell anemia

Journal of Dietary Supplements

Volumn 7, Issue 1, 2010, Pages 21-30

  Obodozie, Obiageli O ^a   Ameh, Sunday J ^a   Afolabi, Ernest K ^a   Oyedele, Eunice O ^a   Ache, Theophilus A ^a   Onanuga, Cordelia E ^a   Ibe, Martha C ^a   Inyang, Uford S ^a  

^a NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Nigeria)

Author keywords

Good manufacturing practice; Herbal medicine; Niprisan ; Normative study; Sickle cell anemia

Indexed keywords

BICARBONATE; MAGADI SODA; NIPRISAN; PLANT EXTRACT;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHEMISTRY; EUGENIA; HERBAL MEDICINE; HUMAN; MEDICINAL PLANT; PH; PHYTOTHERAPY; PIPER (PLANT); PTEROCARPUS; QUALITY CONTROL; REFERENCE VALUE; SICKLE CELL ANEMIA; SORGHUM; SPECIES DIFFERENCE; STANDARD;

ANEMIA, SICKLE CELL; BICARBONATES; EUGENIA; HERBAL MEDICINE; HUMANS; HYDROGEN-ION CONCENTRATION; PHYTOTHERAPY; PIPER; PLANT EXTRACTS; PLANTS, MEDICINAL; PTEROCARPUS; QUALITY CONTROL; REFERENCE VALUES; SORGHUM; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ATOMIC;

FABACEAE; MYRTACEAE; PIPER GUINEENSE; PIPERACEAE; POACEAE; PTEROCARPUS; PTEROCARPUS OSUN; SORGHUM BICOLOR; SYZYGIUM AROMATICUM; TRONA;

EID: 77749283116     PISSN: 19390211     EISSN: None     Source Type: Journal    
DOI: 10.3109/19390210903534988     Document Type: Article

References (16)

1. Ankrah EK, Dovlo FE. The properties of trona and its effect on the cooking time of cowpeas. J Sci Food Agric. 2006;29(11):950-952.
2. Awodogan A, Wambebe C, Gamaniel K, Okogun J, Orisadipe A, Akah P. Acute and short-term toxicity of NIPRISANR- in Rats I: biochemical study. J Pharmaceut Res Dev. 1996;2:39-45.
3. Awosiyan K. Nigeria has highest sickle cell patients. Nigeria Tribune, 14th December, 2006. Lagos, Nigeria, p.1.
4. Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: Iqbal Ahmad, Farrukh Aqil, andMohammad Owais (Eds.), Modern Phytomedicine - TurningMedicinal Plants into Drugs, pp. 25-57. Weinheim, Germany: WILEY-VCH Verlag GmbH & Co. KGaA, 2006.
5. British Pharmacopoeia. British Pharmacopoeia, 2004. Volume IV. The Stationery Office Limited, London. Appendix II D, Atomic spectrophotometry: emission and absorption, pp. A143-145. Determination of pH, pp. A143-145; Appendix VL, Determination of pH Values, pp. A199-A200, 2004.
6. Cordeiro NJV, Oniyangi O. Phytomedicines [medicines derived from plants] for sickle cell disease. The Cochrane Database of Systematic Review 2006 Issue 3. The Cochrane Library (ISSN 1464-780X), 2006.
7. Gamaniel K, Amos S, Akah P, Samuel B, Olusola A, Abayomi O, et al. Pharmacological profile of NIPRD 94/002/1-0: a novel herbal antisickling agent. J Pharmaceut Res Dev. 1998;3(2):89-94.
8. Iyamu EW, Turner EA, Asakawa T. Niprisan [Nix-0699] improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Brit J Haematol. 2003;122(6):1001-1008.
9. Pandey RC. Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN- Granted Orphan Drug Status by the FDA NEW BRUNSWICK, N.J.-(BUSINESS WIRE)-Sept. 2, 2003-Xechem International, Inc. (OTC BB: XKEM). Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN- Granted Orphan Drug Status by. . . (cited November, 20th 2009), 2003.
10. Steinberg MH. Management of sickle cell disease. New Engl J Med. 1999;340(13):1021-1030. http://content.nejm.org/cgi/content/full/3401/1021 Themineral trona - Accessed from: http://minerals.galleries.com/minerals/ carbonate/class.htm (cited November, 20th 2009)
11. Waknine Y. Orphan Drug Niprisan (Nicosan/Hemoxin) for Sickle Cell Disease in EU. International Approvals. October, 2005 http://www.medscape.com/px/ viewindex/more? Bucket=columns§ionId=2557 (cited November, 20th 2009), 2005.
12. Wambebe CO, Elijah AB, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, et al. Efficacy of Niprisan in the prophylactic management of patients with sickle cell disease. Curr Ther Res. 2001;62(1):26-34. ISSN 0011-393X CODEN CTCEA9. Efficacy of niprisan in the prophylactic management of patients with sickle cell disease
13. Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, et al. Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine. 2001 Jul;8(4):252-261. doi:10.1078/0944-7113-00040
14. WHO. Chemistry-Manufacturing-Control (CMC) considerations for herbal products. Information needed to support Clinical Trials of herbal products. 2005. pp. 1-16.
15. WHO. Sickle-cell disease and other haemoglobin disorders. August 2006, WHO, Geneva, Fact sheet N°308, 2006.
16. WHO. 1998. Quality control methods for medicinal plant materials, pp. 1-115. Geneva:WHO, 1998.